Do analysts recommend CALC or ADXN?

CalciMedica currently has a consensus price target of $10.00, indicating a potential upside of 2,053.32%. Given CalciMedica's stronger consensus rating and higher probable upside, research analysts clearly believe CalciMedica is more favorable than Addex Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CalciMedica 1 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.20 Addex Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is CALC or ADXN more profitable?

Addex Therapeutics' return on equity of -134.76% beat CalciMedica's return on equity. Company Net Margins Return on Equity Return on Assets CalciMedica N/A -863.40% -155.24% Addex Therapeutics N/A -134.76% -106.00%

Does the media favor CALC or ADXN?

In the previous week, CalciMedica had 2 more articles in the media than Addex Therapeutics. MarketBeat recorded 6 mentions for CalciMedica and 4 mentions for Addex Therapeutics. Addex Therapeutics' average media sentiment score of 0.42 beat CalciMedica's score of 0.15 indicating that Addex Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CalciMedica 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Addex Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate ADXN or CYCN?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Addex Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Cyclerion Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts rate VYNE or ADXN?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score VYNE Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Addex Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts rate ADXN or ABVC?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Addex Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 ABVC BioPharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is ADXN or ABVC more profitable?

ABVC BioPharma's return on equity of -47.68% beat Addex Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Addex Therapeutics N/A -134.76% -106.00% ABVC BioPharma N/A -47.68% -30.97%

Is LEXX or ADXN more profitable?

Addex Therapeutics' return on equity of -134.76% beat Lexaria Bioscience's return on equity. Company Net Margins Return on Equity Return on Assets Lexaria Bioscience N/A -174.93% -143.89% Addex Therapeutics N/A -134.76% -106.00%

Addex Therapeutics (ADXN) Competitors

$3.84 -0.01 (-0.26%)

As of 08/28/2026 04:00 PM Eastern

Compare

ADXN vs. CALC, CYCN, VYNE, ABVC, and LEXX

Should you buy Addex Therapeutics stock or one of its competitors? Addex Therapeutics's main competitors and comparable companies include CalciMedica (CALC), Cyclerion Therapeutics (CYCN), VYNE Therapeutics (VYNE), ABVC BioPharma (ABVC), and Lexaria Bioscience (LEXX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Addex Therapeutics compare to CalciMedica?

CalciMedica (NASDAQ:CALC) and Addex Therapeutics (NASDAQ:ADXN) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, profitability, earnings, institutional ownership, risk, dividends and valuation.

CalciMedica currently has a consensus price target of $10.00, indicating a potential upside of 2,053.32%. Given CalciMedica's stronger consensus rating and higher probable upside, research analysts clearly believe CalciMedica is more favorable than Addex Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CalciMedica	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20
Addex Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

CalciMedica has a beta of 0.91, suggesting that its stock price is 9% less volatile than the broader market. Comparatively, Addex Therapeutics has a beta of 1.5, suggesting that its stock price is 50% more volatile than the broader market.

In the previous week, CalciMedica had 2 more articles in the media than Addex Therapeutics. MarketBeat recorded 6 mentions for CalciMedica and 4 mentions for Addex Therapeutics. Addex Therapeutics' average media sentiment score of 0.42 beat CalciMedica's score of 0.15 indicating that Addex Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CalciMedica	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Addex Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Addex Therapeutics' return on equity of -134.76% beat CalciMedica's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CalciMedica	N/A	-863.40%	-155.24%
Addex Therapeutics	N/A	-134.76%	-106.00%

Addex Therapeutics has higher revenue and earnings than CalciMedica. Addex Therapeutics is trading at a lower price-to-earnings ratio than CalciMedica, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CalciMedica	N/A	N/A	-$29.56M	-$1.36	N/A
Addex Therapeutics	$210K	22.49	-$8.12M	-$5.94	N/A

16.1% of Addex Therapeutics shares are held by institutional investors. 28.3% of CalciMedica shares are held by company insiders. Comparatively, 15.0% of Addex Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

CalciMedica and Addex Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

How does Addex Therapeutics compare to Cyclerion Therapeutics?

Addex Therapeutics (NASDAQ:ADXN) and Cyclerion Therapeutics (NASDAQ:CYCN) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, media sentiment, profitability, institutional ownership, dividends, earnings, analyst recommendations and valuation.

Addex Therapeutics has a beta of 1.5, meaning that its share price is 50% more volatile than the broader market. Comparatively, Cyclerion Therapeutics has a beta of 1.76, meaning that its share price is 76% more volatile than the broader market.

16.1% of Addex Therapeutics shares are owned by institutional investors. Comparatively, 75.6% of Cyclerion Therapeutics shares are owned by institutional investors. 15.0% of Addex Therapeutics shares are owned by insiders. Comparatively, 34.3% of Cyclerion Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Addex Therapeutics had 2 more articles in the media than Cyclerion Therapeutics. MarketBeat recorded 4 mentions for Addex Therapeutics and 2 mentions for Cyclerion Therapeutics. Addex Therapeutics' average media sentiment score of 0.42 beat Cyclerion Therapeutics' score of -0.07 indicating that Addex Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Addex Therapeutics	Neutral
Cyclerion Therapeutics	Neutral

Addex Therapeutics has a net margin of 0.00% compared to Cyclerion Therapeutics' net margin of -170.11%. Cyclerion Therapeutics' return on equity of -87.96% beat Addex Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Addex Therapeutics	N/A	-134.76%	-106.00%
Cyclerion Therapeutics	-170.11%	-87.96%	-74.86%

Cyclerion Therapeutics has higher revenue and earnings than Addex Therapeutics. Cyclerion Therapeutics is trading at a lower price-to-earnings ratio than Addex Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Addex Therapeutics	$210K	22.49	-$8.12M	-$5.94	N/A
Cyclerion Therapeutics	$2.07M	8.57	-$3.53M	-$1.66	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Addex Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Cyclerion Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Cyclerion Therapeutics beats Addex Therapeutics on 8 of the 13 factors compared between the two stocks.

How does Addex Therapeutics compare to VYNE Therapeutics?

VYNE Therapeutics (NASDAQ:VYNE) and Addex Therapeutics (NASDAQ:ADXN) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, dividends, risk, analyst recommendations, institutional ownership, valuation and earnings.

Addex Therapeutics has a net margin of 0.00% compared to VYNE Therapeutics' net margin of -4,726.21%. VYNE Therapeutics' return on equity of -70.42% beat Addex Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
VYNE Therapeutics	-4,726.21%	-70.42%	-63.46%
Addex Therapeutics	N/A	-134.76%	-106.00%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
VYNE Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Addex Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

83.8% of VYNE Therapeutics shares are held by institutional investors. Comparatively, 16.1% of Addex Therapeutics shares are held by institutional investors. 3.0% of VYNE Therapeutics shares are held by insiders. Comparatively, 15.0% of Addex Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Addex Therapeutics has lower revenue, but higher earnings than VYNE Therapeutics. VYNE Therapeutics is trading at a lower price-to-earnings ratio than Addex Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
VYNE Therapeutics	$570K	33.29	-$26.48M	-$0.38	N/A
Addex Therapeutics	$210K	22.49	-$8.12M	-$5.94	N/A

VYNE Therapeutics has a beta of 2, suggesting that its stock price is 100% more volatile than the broader market. Comparatively, Addex Therapeutics has a beta of 1.5, suggesting that its stock price is 50% more volatile than the broader market.

In the previous week, Addex Therapeutics had 4 more articles in the media than VYNE Therapeutics. MarketBeat recorded 4 mentions for Addex Therapeutics and 0 mentions for VYNE Therapeutics. Addex Therapeutics' average media sentiment score of 0.42 beat VYNE Therapeutics' score of 0.00 indicating that Addex Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
VYNE Therapeutics	Neutral
Addex Therapeutics	Neutral

Summary

VYNE Therapeutics beats Addex Therapeutics on 7 of the 13 factors compared between the two stocks.

How does Addex Therapeutics compare to ABVC BioPharma?

Addex Therapeutics (NASDAQ:ADXN) and ABVC BioPharma (NASDAQ:ABVC) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, media sentiment, risk, profitability, dividends and earnings.

Addex Therapeutics has a beta of 1.5, suggesting that its share price is 50% more volatile than the broader market. Comparatively, ABVC BioPharma has a beta of 0.57, suggesting that its share price is 43% less volatile than the broader market.

16.1% of Addex Therapeutics shares are owned by institutional investors. Comparatively, 11.4% of ABVC BioPharma shares are owned by institutional investors. 15.0% of Addex Therapeutics shares are owned by insiders. Comparatively, 19.0% of ABVC BioPharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

ABVC BioPharma has higher revenue and earnings than Addex Therapeutics. ABVC BioPharma is trading at a lower price-to-earnings ratio than Addex Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Addex Therapeutics	$210K	22.49	-$8.12M	-$5.94	N/A
ABVC BioPharma	$510K	43.37	-$7.91M	-$0.30	N/A

In the previous week, Addex Therapeutics had 3 more articles in the media than ABVC BioPharma. MarketBeat recorded 4 mentions for Addex Therapeutics and 1 mentions for ABVC BioPharma. ABVC BioPharma's average media sentiment score of 1.89 beat Addex Therapeutics' score of 0.42 indicating that ABVC BioPharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Addex Therapeutics	Neutral
ABVC BioPharma	Very Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Addex Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
ABVC BioPharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

ABVC BioPharma's return on equity of -47.68% beat Addex Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Addex Therapeutics	N/A	-134.76%	-106.00%
ABVC BioPharma	N/A	-47.68%	-30.97%

Summary

ABVC BioPharma beats Addex Therapeutics on 8 of the 12 factors compared between the two stocks.

How does Addex Therapeutics compare to Lexaria Bioscience?

Lexaria Bioscience (NASDAQ:LEXX) and Addex Therapeutics (NASDAQ:ADXN) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, profitability, risk, earnings, dividends and institutional ownership.

In the previous week, Addex Therapeutics had 2 more articles in the media than Lexaria Bioscience. MarketBeat recorded 4 mentions for Addex Therapeutics and 2 mentions for Lexaria Bioscience. Lexaria Bioscience's average media sentiment score of 0.96 beat Addex Therapeutics' score of 0.42 indicating that Lexaria Bioscience is being referred to more favorably in the media.

Company	Overall Sentiment
Lexaria Bioscience	Positive
Addex Therapeutics	Neutral

Addex Therapeutics has lower revenue, but higher earnings than Lexaria Bioscience. Lexaria Bioscience is trading at a lower price-to-earnings ratio than Addex Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lexaria Bioscience	$710K	24.05	-$11.90M	-$5.10	N/A
Addex Therapeutics	$210K	22.49	-$8.12M	-$5.94	N/A

Addex Therapeutics' return on equity of -134.76% beat Lexaria Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lexaria Bioscience	N/A	-174.93%	-143.89%
Addex Therapeutics	N/A	-134.76%	-106.00%

Lexaria Bioscience has a beta of 0.38, meaning that its share price is 62% less volatile than the broader market. Comparatively, Addex Therapeutics has a beta of 1.5, meaning that its share price is 50% more volatile than the broader market.

13.1% of Lexaria Bioscience shares are owned by institutional investors. Comparatively, 16.1% of Addex Therapeutics shares are owned by institutional investors. 8.4% of Lexaria Bioscience shares are owned by company insiders. Comparatively, 15.0% of Addex Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Lexaria Bioscience currently has a consensus price target of $22.50, suggesting a potential upside of 117.39%. Given Lexaria Bioscience's stronger consensus rating and higher possible upside, equities research analysts clearly believe Lexaria Bioscience is more favorable than Addex Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lexaria Bioscience	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Addex Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Addex Therapeutics beats Lexaria Bioscience on 8 of the 15 factors compared between the two stocks.

Get Addex Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ADXN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ADXN vs. The Competition

Export

Metric	Addex Therapeutics	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$4.73M	$12.17B	$7.21B	$12.90B
Dividend Yield	N/A	2.62%	2.54%	11.28%
P/E Ratio	-0.65	787.65	273.16	25.42
Price / Sales	22.49	756.04	629.76	95.09
Price / Cash	N/A	15.32	28.74	36.03
Price / Book	0.82	10.49	11.08	6.36
Net Income	-$8.12M	$2.83B	$3.48B	$349.79M
7 Day Performance	-22.27%	0.39%	0.13%	-0.80%
1 Month Performance	-31.31%	5.34%	7.08%	4.13%
1 Year Performance	-52.33%	6.05%	24.67%	15.17%

Addex Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ADXN Addex Therapeutics	0.3823 of 5 stars	$3.84 -0.3%	N/A	-52.3%	$4.73M	$210K	N/A	30	News Coverage Short Interest Increase
CALC CalciMedica	4.0148 of 5 stars	$0.59 -0.1%	$10.00 +1,602.1%	-82.8%	$20.06M	N/A	N/A	30	News Coverage Analyst Upgrade Short Interest Decrease
CYCN Cyclerion Therapeutics	0.6174 of 5 stars	$4.15 +3.8%	N/A	+50.1%	$19.42M	$2.07M	N/A	30
VYNE VYNE Therapeutics	0.0499 of 5 stars	$28.33 -0.8%	N/A	+76.8%	$18.98M	$570K	N/A	30	Gap Down High Trading Volume
ABVC ABVC BioPharma	0.826 of 5 stars	$0.71 -11.1%	N/A	-70.7%	$18.95M	$510K	N/A	30	Positive News Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ADXN) was last updated on 8/30/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Addex Therapeutics (ADXN) Competitors

ADXN vs. CALC, CYCN, VYNE, ABVC, and LEXX

How does Addex Therapeutics compare to CalciMedica?

Summary

How does Addex Therapeutics compare to Cyclerion Therapeutics?

Summary

How does Addex Therapeutics compare to VYNE Therapeutics?

Summary

How does Addex Therapeutics compare to ABVC BioPharma?

Summary

How does Addex Therapeutics compare to Lexaria Bioscience?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADXN vs. The Competition

Addex Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Addex Therapeutics (ADXN) Competitors

ADXN vs. CALC, CYCN, VYNE, ABVC, and LEXX

How does Addex Therapeutics compare to CalciMedica?

Do analysts recommend CALC or ADXN?

Which has more risk & volatility, CALC or ADXN?

Does the media favor CALC or ADXN?

Is CALC or ADXN more profitable?

Which has stronger earnings & valuation, CALC or ADXN?

Do insiders and institutionals believe in CALC or ADXN?

Summary

How does Addex Therapeutics compare to Cyclerion Therapeutics?

Which has more risk & volatility, ADXN or CYCN?

Do institutionals & insiders believe in ADXN or CYCN?

Does the media favor ADXN or CYCN?

Is ADXN or CYCN more profitable?

Which has better valuation and earnings, ADXN or CYCN?

Do analysts rate ADXN or CYCN?

Summary

How does Addex Therapeutics compare to VYNE Therapeutics?

Is VYNE or ADXN more profitable?

Do analysts rate VYNE or ADXN?

Do institutionals and insiders hold more shares of VYNE or ADXN?

Which has stronger valuation and earnings, VYNE or ADXN?

Which has more volatility & risk, VYNE or ADXN?

Does the media prefer VYNE or ADXN?

Summary

How does Addex Therapeutics compare to ABVC BioPharma?

Which has more volatility and risk, ADXN or ABVC?

Do insiders & institutionals have more ownership in ADXN or ABVC?

Which has higher valuation and earnings, ADXN or ABVC?

Does the media prefer ADXN or ABVC?

Do analysts rate ADXN or ABVC?

Is ADXN or ABVC more profitable?

Summary

How does Addex Therapeutics compare to Lexaria Bioscience?

Does the media refer more to LEXX or ADXN?

Which has higher earnings and valuation, LEXX or ADXN?

Is LEXX or ADXN more profitable?

Which has more risk and volatility, LEXX or ADXN?

Do insiders and institutionals hold more shares of LEXX or ADXN?

Do analysts recommend LEXX or ADXN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADXN vs. The Competition

Addex Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools